Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Peginterferon α-2a for the treatment of HIV infection.
Asmuth DM, Utay NS, Pollard RB. Asmuth DM, et al. Expert Opin Investig Drugs. 2016;25(2):249-57. doi: 10.1517/13543784.2016.1132699. Epub 2016 Jan 4. Expert Opin Investig Drugs. 2016. PMID: 26667398 Review.
Treatments for hepatitis B.
Asmuth DM, Nguyen HH, Melcher GP, Cohen SH, Pollard RB. Asmuth DM, et al. Clin Infect Dis. 2004 Nov 1;39(9):1353-62. doi: 10.1086/425010. Epub 2004 Oct 12. Clin Infect Dis. 2004. PMID: 15494913 Review.
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis.
Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB; AACTG 266 Team. Borucki MJ, et al. Among authors: asmuth dm. Antiviral Res. 2004 Nov;64(2):103-11. doi: 10.1016/j.antiviral.2004.06.012. Antiviral Res. 2004. PMID: 15498605 Clinical Trial.
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
Lori F, Pollard RB, Whitman L, Bakare N, Blick G, Shalit P, Foli A, Peterson D, Tennenberg A, Schrader S, Rashbaum B, Farthing C, Herman D, Norris D, Greiger P, Frank I, Groff A, Lova L, Asmuth D, Lisziewicz J. Lori F, et al. AIDS Res Hum Retroviruses. 2005 Apr;21(4):263-72. doi: 10.1089/aid.2005.21.263. AIDS Res Hum Retroviruses. 2005. PMID: 15943568 Clinical Trial.
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.
Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS, Shafer RW, Robbins GK, Pollard RB; ACTG 384 Team. Gandhi RT, et al. Among authors: asmuth dm. J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34. doi: 10.1097/01.qai.0000226789.51992.3f. J Acquir Immune Defic Syndr. 2006. PMID: 16810109 Clinical Trial.
79 results